For Q1 FY2026 ended March 31, 2026, EyePoint reported revenue of $696,000, a 97.2% decline year-over-year. Net loss was $84.8 million, up 87.7% from the prior year, with diluted EPS of -$0.99. Operating loss widened to $87.2 million. Cash stood at $77.7 million, and equity was $230.5 million.
•Revenue fell 97.2% YoY to $696,000.
•Net loss increased 87.7% to $84.8 million.
•Diluted EPS was -$0.99, a 52.3% larger loss per share.
•Cash and equity were $77.7 million and $230.5 million, respectively.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
EyePoint develops and commercializs therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. Founded in 2000 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as EyePoint Pharmaceuticals, Inc. before rebranding in December 2025.
EyePoint, Inc. is a biotechnology company focused on developing and commercializing therapeutics for serious retinal diseases. Its pipeline leverages the proprietary Durasert E technology, a bioerodible system for sustained intraocular drug delivery. The lead product candidate is DURAVYU, an investigational treatment combining vorolanib (a selective tyrosine kinase inhibitor) with Durasert E for vascular endothelial growth factor mediated retinal diseases. DURAVYU is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Another pipeline program is EYP-2301, a TIE-2 agonist formulated in Durasert E, currently in pre-clinical development to potentially improve outcomes in serious retinal diseases.
Where is EyePoint, Inc. (EYPT) listed and what currency is used?
EyePoint, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol EYPT. The company operates in the United States and its financials are reported in US Dollars (USD). As a Nasdaq-listed company, it is subject to US securities regulations and reporting standards.
What sector and industry does EyePoint, Inc. (EYPT) belong to?
EyePoint, Inc. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of therapies for medical conditions, particularly serious retinal diseases. The company's work involves advanced drug delivery technologies and clinical-stage product candidates targeting eye diseases like wet age-related macular degeneration and diabetic macular edema.
Where is EyePoint, Inc. (EYPT) headquartered and what is its history?
EyePoint, Inc. is headquartered in Watertown, Massachusetts, United States. The company was founded in 2000 and was formerly known as EyePoint Pharmaceuticals, Inc. before rebranding to EyePoint, Inc. in December 2025. The company primarily serves the US market, focusing on developing treatments for retinal diseases.
What is the main technology behind EyePoint, Inc.'s (EYPT) product pipeline?
The core technology of EyePoint, Inc. is its proprietary Durasert E system, a bioerodible platform designed for sustained intraocular drug delivery. This technology allows for controlled release of therapeutics directly into the eye over an extended period, potentially reducing the need for frequent injections. The lead candidate DURAVYU uses Durasert E to deliver vorolanib, a tyrosine kinase inhibitor, for retinal diseases. Another early-stage program, EYP-2301, employs Durasert E to deliver a TIE-2 agonist. This technology is central to the company's strategy for treating chronic retinal conditions.